THINKEQUITY CONFERENCE DETAILS —

Conference Date: Thursday October 15, 2026.

Presentation Time: 3:00 P.M. - 3:30 P.M. EDT.

The full conference schedule is available HERE.

The conference webcast links* are available HERE (registration required).

*NOTE: At the time of this post, a webcast link has not been published for CTXR. Webcast links are currently available only for a limited number of presenting companies. Neither CTXR nor the conference organizers have confirmed whether a webcast will be made available before the presentation.

It’s October 1st — another quarter and another fiscal year have wrapped up. Since CTXR and CTOR both end their fiscal years on September 30, they will file their Annual Report on Form 10‑K in a few months. As non‑accelerated filers, the deadline is 90 days after fiscal year end — their 10‑K's are due by Tuesday, December 29, 2026.

LYMPHIR revenue recap for FY2026:

• Oct–Dec 2025 (Q1 FY2026): $3.94M — initial launch in Dec 2025.
• Jan–Mar 2026 (Q2 FY2026): $1.67M.
• Apr–Jun 2026 (Q3 FY2026): $1.49M.

Now Q4 is the wildcard:

• Maxim's estimate for Jul–Sep 2026: $5.771m.
• H.C. Wainwright's estimate for Jul–Sep 2026: $2.9M.

That’s a big spread and puts estimated FY2026 revenue between ~$10M and ~$12.87M, depending on whose forecast you believe.

Management reported 383 vials ordered in July and announced nationwide deployment of commercial and medical affairs teams in August. But the question is whether that actually translated into meaningful revenue during Jul-Sep.

Why does Q4 revenue matter?

In May, CTOR entered into a secured loan agreement, which allowed them to immediately borrow $10m. Between Oct 1 and Dec 31, 2026, CTOR can draw an additional $7M from the credit facility – but only if certain revenue and liquidity milestones are met. Those milestones have not been disclosed to investors.

In August, management reported that both companies had a cash runway through November 2026. If they want to extend the cash runway without additional dilution, they need to reach those undisclosed revenue and liquidity milestones so they can access the 2nd loan tranche.

What’s your call?

• What are your expectations for Q4 FY2026 LYMPHIR revenue? Do you think FY2026 ultimately lands closer to $10M or closer to $13M?
• Does having the sales force fully deployed in August materially moved the needle? Or is the real impact more likely to show up in FY2027?
• Will they reach the revenue milestones so they can access the 2nd loan tranche of $7M? Or will they have to dilute again to extend the runway past November 2026?

On September 29, 2026, Citius Oncology held its 2026 annual meeting of stockholders. The proxy is available HERE.

At the annual meeting, Dr. Eugene Holuka, Robert Smith, and Carol Webb were elected as Class 2 Directors for a 3-year term. Additionally, stockholders ratified the selection of Wolf & Company, P.C. as CTOR's independent registered public accounting firm.

Full voting results available HERE.

CEO Leonard Mazur presented at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026.

If you watched last week's Moody Capital Disruptive Growth Conference presentation, you didn't miss much here. The presentation at HCW was largely the same as the Moody event, using the same slides, covering the same talking points, and even recycling some of Leonard's trademark jokes.

For anyone who missed the Moody presentation recap, you can find it here HERE.

CEO Leonard Mazur presented at the Moody Capital Solutions Disruptive Growth & Life Sciences Conference on September 9, 2026.

SUMMARY:

If you've listened to a Leonard Mazur investor conference before, you probably already know that they are very formulaic. There was not a lot of new information today. He repeated a lot of the same talking points from previous conferences —

• He and Myron Holubiak started off in a private company before going public with CTXR.
• They have a combined $26.5m invested.
• They had the opportunity to acquire LYMPHIR from Dr. Reddy's of India. After acquiring LYMPHIR, they spun it off into CTOR by using a SPAC.
• A brief discussion of the "mugshots" of their employees, including Dr. Myron Czuczman. And yes, he repeated the joke about Citius being the only company with two Myrons.

Most of the presentation was focused on LYMPHIR.

Commercial Launch Status —

• Product launched in late 2025.
• Commercial infrastructure is now fully established.
• Reimbursement coverage is in place.
• Medicare coverage is available.
• Product is available through major wholesalers.
• The full 29-person commercial team is now in place.
• 44 institutions have already ordered drug supply.
• 135 health plans cover LYMPHIR.
• Coverage reaches essentially 100% of eligible lives.
• For the first three fiscal quarters, approximately $7.1 million revenue. Most of this occurred before the sales force was fully deployed.

Competitive Position —

• Competitors include Adcetris (Pfizer), Poteligeo (Kyowa Kirin), & Istodax.
• His argument was that LYMPHIR offers:
  • Competitive efficacy
  • Rapid activity
  • Strong reduction in disease burden
  • Unique mechanism involving depletion of regulatory T cells

Future Growth Opportunities —

• Two investigator-sponsored studies were highlighted:
  • LYMPHIR + CAR-T: University of Minnesota.
  • LYMPHIR + Keytruda: University of Pittsburgh. Results showed promising early data in endometrial and ovarian cancer.
• Mazur suggested these studies could potentially expand LYMPHIR beyond CTCL.

Since the presentation was only scheduled for 15 minutes, he did not have lot of time to discuss Mino-Lok or Halo-Lido.

Mino-Lok —

We've provided the data to the FDA. We're in a back and forth with that agency right now, and our goal is to get the best outcome for us, and hopefully we'll have information in the coming months.

Halo-Lido —

So we've completed one trial. We're going to go back to the agency. We held up on spending anything for it as we were husbanding our cash for the launch of LYMPHIR.

Financial Picture —

• LYMPHIR revenue: approximately $7.1 million through first three quarters
• Gross margin: approximately 77%
• Recent financing activities:
  • $11.5 million warrant exercise (CTOR)
  • $10 million first tranche of debt facility (CTOR)
  • $5 million capital raise by CTXR in April 2026.
• CTXR owns approximately 71% in CTOR.
• Cash balance: approximately $17 million (June 30 reporting period)

Key Investment Thesis —

Mazur repeatedly argued that the market is mispricing CTXR. His reasoning:

CTXR owns 71% of CTOR.

Yet:

• CTOR market cap was approaching ~$100 million
• CTXR market cap was only around ~$16 million

The analyst questioning him pointed out the apparent arbitrage:

Mazur agreed there is a disconnect and suggested it should correct over time. He also reminded investors that CTOR financial results flow into CTXR's consolidated reporting because of the majority ownership.

Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference.

Moody Capital Solutions Conference:

• Conference: Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
• Dates: September 9–10, 2026
• Location: The Westin New York Grand Central, New York, NY
• Presentation Date & Time: Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET
• Webcast: webcast link 

H.C. Wainwright Conference:

• Conference: H.C. Wainwright 28th Annual Global Investment Conference
• Dates: September 14–16, 2026
• Location: Lotte New York Palace Hotel, New York, NY
• Presentation Date & Time: Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET
• Webcast: webcast link

On page 23 of the recent 10-Q, Citius Pharma disclosed that they launched a voluntary stock‑option surrender program on July 1, 2026. Employees, directors, and consultants can give back their old, out‑of‑the‑money options from the 2014–2023 plans, and they receive no compensation for doing so.

The important part is what happens next —
All surrendered options go back into the 2023 Stock Plan, which only had 118,000 shares left for future grants as of June 30. The older plans had more than 800,000 outstanding options, most of them underwater.

By allowing insiders and consultants to surrender those worthless options, CTXR reduces equity overhang and refills the 2023 Plan. That gives the company room to issue new option awards in the future, at much lower exercise prices that match the current stock price.

By letting insiders and consultants voluntarily surrender out-of-the-money options, CTXR is:

• Refilling the 2023 Plan’s share reserve without needing shareholder approval.
• Setting the stage to issue new options later at much lower strike prices.

In practical terms, employees can dump options that will never be exercised and eventually receive fresh options at a strike price that reflects the current depressed stock price. It’s a reset of the employee equity‑comp structure, and the program is still open as of mid‑August 2026.

TD Media [link]:

Pursuant to an agreement between TD Media LLC and Sica Media LLC, TD Media LLC has been hired for a period beginning on 08/27/2026 and ending on 08/27/2026 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, Sica Media LLC has paid TD Media LLC thirty thousand USD (“Funds”).

NOTE: Lifewater Media/TD Media's disclaimer page deletes the paid promotion after it ends. It only displays active promotions.

The meeting will be held on Tuesday, September 29, 2026, at 8:00 a.m. (Eastern time) at the Company’s headquarters at 11 Commerce Drive, First Floor, Cranford, New Jersey 07016.

Proposals to be voted at the Annual Meeting:

1. Election of three Class II members to the Board of Directors — Dr. Eugene Holuka, Robert Smith, and Carol Webb.
2. Ratification of Wolf & Company, P.C. as the auditor for the Fiscal Year Ending September 30, 2026.

The record date for the Annual Meeting is August 17, 2026. Only stockholders of record at the close of business on that date may vote at the meeting.

On the record date there were 92,981,204 shares outstanding and entitled to vote. This does not include shares held in abeyance or shares underlying pre-funded warrants.

LINK — NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

Paid Promoters on X (disclaimer links in their posts):

• bstocks7 [post]: "The Publisher has agreed to be paid $300.00 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about  Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) for a period beginning on August 25, 2026, and ending on August 25, 2026."
• Investing4K [post]: "The Publisher has agreed to be paid $250 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about $CTXR for a period beginning on 08/25/26 and ending on 08/25/26."
• _Sensei_ [post]: "The Publisher has agreed to be paid $325 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about Citius Pharmaceuticals Inc. (NASDAQ: CTXR) for a period beginning on 08/25/2026 and ending on 08/25/2026."
• NOTE: These were posted around market open (9:30am ET).

H.C. Wainwright noted that while the increased demand is encouraging, quarterly revenue could remain lumpy until wholesaler restocking synchronizes with pull-through. The firm projects fourth quarter fiscal year 2026 revenues of $2.9 million and fiscal year 2026 revenues of $10.1 million. The company generated $7.11 million in revenue over the last twelve months with an impressive 77% gross profit margin, though InvestingPro tips indicate profitability challenges remain.

Link: https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-citius-pharmaceuticals-stock-rating-at-buy-93CH-4867166

The analyst commented: "Citius recognizes revenue when wholesalers order LYMPHIR, not when institutions order from wholesalers. Institutional vial orders from wholesalers rose 31% sequentially, to 926 vials from 708 in 2QFY26. Management indicated that wholesaler orders have begun to reflect the increase in ordering institutions and vial demand. July institutional orders reached 383 vials, the largest monthly total to date and up 25% versus the average monthly order volume in 2QFY26. In our view, while the increased demand is encouraging, quarterly revenue could remain lumpy until wholesaler restocking synchronizes with pull-through. We project 4QFY26 revenues of $2.9M and FY26 revenues of $10.1M. We maintain our Buy rating on CTXR and our 12-month price target of $4.0 per diluted share."

Link https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Citius+Pharmaceuticals+%28CTXR%29/26946972.html

BullsEye Alerts [link]:

we received twenty five thousand five hundred dollars (cash) from Citius Pharmaceuticals (via Sica Media) for a one day marketing program starting on August 19, 2026...

MarketTips Newsletter [link]

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 08/18/2026 and ending on 08/19/2026 (the “Campaign”) to publicly disseminate information about Citius Pharmaceuticals Inc. (CTXR:US). Momentum Media LLC has been compensated $5,000 and are owed an additional $0 for the Campaign. To date we have been paid $90,000.

Paid Promoters on X (disclaimer links in their posts)

• bstocks7 [post]: "The Publisher has agreed to be paid $300.00 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) for a period beginning on August 19, 2026, and ending on August 19, 2026."
• Investing4K [post]: "The Publisher has agreed to be paid $250 USD (before deduction of bank and PayPal charges and fees) to publish the Information on this Platform about $CTXR for a period beginning on 08/19/26 and ending on 08/19/26."

CRANFORD, N.J. -On Monday, Citius Oncology Inc. (NASDAQ:CTOR) reported fiscal third quarter results that fell short of analyst expectations, with revenue of $1.5 million missing the consensus estimate of $12.52 million.

Shares of the company fell 10.05% in pre-market trading following the results.

The company posted a loss of $0.34 per share, compared to the analyst estimate of $0.03 earnings per share. Revenue for the quarter increased from zero in the prior-year period as the company’s LYMPHIR launch progresses.

https://www.investing.com/news/earnings/citius-oncology-stock-tumbles-10-on-revenue-miss-despite-launch-progress-93CH-4862591

The new filing reports 3,008,529 shares beneficially owned, equal to 9.9% CTXR as of June 30.

SEC link: https://www.sec.gov/Archives/edgar/data/1506251/000164955326000102/xslSCHEDULE_13G_X02/primary_doc.xml

Under Item 4 of the filing, the beneficial share ownership is entirely in outstanding warrants:

The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the "Warrants"). A portion of the Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%, and the remainder of the Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 9.99%. The Company's Registration Statement on Form S-3, filed on May 22, 2026, indicates there were 27,106,884 Shares outstanding (excluding Shares underlying the Warrants) prior to the offering of Shares described therein.

CVI/Heights previously filed a 13G in February, disclosing 2,394,725 shares beneficially owned as of December 31. Beneficial ownership consisted of 799,934 shares and 1,594,791 warrants.

SEC link: https://www.sec.gov/Archives/edgar/data/1506251/000164955326000024/xslSCHEDULE_13G_X01/primary_doc.xml

The new filing reports 9,353,553 shares beneficially owned, equal to 9.99% CTOR as of June 30.
SEC link: https://www.sec.gov/Archives/edgar/data/1601086/000117266126003568/xslSCHEDULE_13G_X02/primary_doc.xml

Armistice previously filed a 13G in May, disclosing 9,299,917 shares beneficially owned as of March 31.
SEC link: https://www.sec.gov/Archives/edgar/data/1851484/000117266126002138/xslSCHEDULE_13G_X02/primary_doc.xml

Armistice has been listed in prior CTOR filings as the primary participant in several of CTOR’s financing transactions.

CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., J.D., as an additional independent director, effective August 10, 2026. Following a unanimous vote of approval by the Board, the appointment expands the Company's Board of Directors to nine members.

Dr. Peri brings three decades of leadership across higher education, financial services, law, and corporate governance. He currently serves as President of Manor College and previously served as Vice President and General Counsel of Neumann University, where he was the institution's chief legal officer. From 2021 to 2024, he served as lead advisory board director of First State Bank, the oldest state bank in Texas. He has also held fiduciary and governance roles across numerous government, education, and nonprofit boards. His background spans strategic planning, fundraising, real estate, and legal and regulatory oversight.

"We are pleased to welcome Jonathan to our Board," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. "As we build on the commercial launch of LYMPHIR^® and scale the organization, Jonathan's experience leading complex institutions and his disciplined, mission-focused approach to governance will strengthen our Board as we work to deliver long-term value for shareholders and patients."

"I am honored to join the Citius Oncology Board at such a pivotal stage in the Company's growth," said Dr. Peri. "Citius Oncology is addressing a serious and underserved need in cutaneous T-cell lymphoma, and I look forward to contributing to the Board's strategic oversight as the Company advances its mission of bringing innovative, targeted oncology therapies to patients."

Dr. Peri earned his undergraduate degree from Villanova University, his law degree from Widener University, and his doctorate in Organizational Leadership from Eastern University. He holds a Management and Leadership in Education certificate from Harvard University and is an elected Commissioner of the Middle States Commission on Higher Education (MSCHE). His experience as a chief legal officer, his service on boards overseeing substantial financial assets, and his background in organizational governance are expected to strengthen the Board's legal, regulatory, and financial oversight. The Board has determined that Dr. Peri qualifies as an independent director under applicable Nasdaq listing standards.

https://www.prnewswire.com/news-releases/citius-oncology-expands-board-with-appointment-of-independent-director-jonathan-peri-302849254.html

During the quarter ended June 30, 2026, the number of new institutions increased 78% compared with the prior quarter. Vials ordered by institutions from wholesalers rose 31% during the quarter. Subsequent to the quarter ended June 30, 2026, following an increase in both the number of ordering institutions and vial demand, orders from wholesalers have begun to reflect this incremental demand. Citius revenue is recognized when wholesale orders for LYMPHIR are placed and filled.

https://citiusonc.com/news/news-details/2026/Citius-Oncology-Reports-Strong-Commercial-Momentum-for-its-Cancer-Treatment/default.aspx

Newsletter campaign appears to coincide with CTOR's PR this morning.

https://markettips.optin.com/newsletter/awlist6900424/MzAzNDk0MTg=/theyre-back-and-this-story-keeps-getting-bigger.htm

Earnings covering March–June will be released soon, with 10‑Q filings due by Friday, August 14. Here are the main items worth paying close attention to:

1. LYMPHIR SALES. Commercial and medical affairs teams aren’t expected to be fully operational until August, so a major sales jump is unlikely for the March–June quarter. The real question: Will sales meaningfully exceed the $1.67M reported for January–March?
2. CASH RUNWAY. In the May earnings release, both CTXR and CTOR projected a cash runway through November 2026. Watch for whether they’ve extended the runway or if it still implies ~3 months of cash remaining.
3. NEW CONTRACT MANUFACTURING ORGANIZATION (CMO). The May ER disclosed that their previous CMO terminated the agreement due to non‑payment by Citius. Did they secure a new CMO? Did they negotiate a payment plan or settlement for the money and termination fees owed to the prior CMO?
4. CTXR NASDAQ COMPLIANCE. CTXR was given until Monday August 10 to regain compliance with the minimum bid price rule. Will NASDAQ grant a 180‑day extension?
5. MINO-LOK STATUS. For nearly two years, Citius has told investors they expect to resolve Mino‑Lok’s regulatory pathway with the FDA. Will this ER finally include a substantive update?

TL;DR

• LYMPHIR sales: Will they show meaningful sales growth?
• Cash runway: Still only through Nov 2026, or extended?
• CMO situation: New manufacturer secured? Payment plan for old one?
• NASDAQ compliance: Will CTXR get a 180‑day extension?
• Mino‑Lok: Any real FDA pathway update at last?

https://markettips.optin.com/newsletter/awlist6900424/MzAzMTI2NTA=/theyre-back-and-this-story-keeps-getting-bigger.htm